Johnson & Johnson (NYSE:JNJ) Shares Bought by Vident Investment Advisory LLC

Vident Investment Advisory LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 25.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,948 shares of the company’s stock after acquiring an additional 8,228 shares during the period. Vident Investment Advisory LLC’s holdings in Johnson & Johnson were worth $5,759,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of JNJ. Austin Private Wealth LLC lifted its stake in shares of Johnson & Johnson by 2.5% during the 1st quarter. Austin Private Wealth LLC now owns 2,830 shares of the company’s stock worth $371,000 after purchasing an additional 68 shares during the period. Sun Life Financial INC lifted its position in Johnson & Johnson by 2.5% during the first quarter. Sun Life Financial INC now owns 2,758 shares of the company’s stock worth $362,000 after buying an additional 68 shares during the period. Winslow Evans & Crocker Inc. lifted its position in Johnson & Johnson by 0.3% during the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after buying an additional 69 shares during the period. Old North State Trust LLC boosted its stake in Johnson & Johnson by 0.5% in the 2nd quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock worth $1,922,000 after buying an additional 71 shares during the last quarter. Finally, Modus Advisors LLC grew its holdings in Johnson & Johnson by 2.0% in the 1st quarter. Modus Advisors LLC now owns 3,666 shares of the company’s stock valued at $481,000 after buying an additional 73 shares during the period. Hedge funds and other institutional investors own 68.44% of the company’s stock.

JNJ opened at $145.76 on Friday. The firm’s 50 day moving average is $144.04 and its 200-day moving average is $144.14. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $383.76 billion, a P/E ratio of 21.31, a P/E/G ratio of 3.23 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. During the same period last year, the business earned $2.58 EPS. The business’s revenue was down 10.8% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend is Monday, August 24th. Johnson & Johnson’s payout ratio is 46.54%.

A number of equities research analysts recently issued reports on JNJ shares. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price for the company. in a report on Tuesday, July 7th. Bank of America reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. ValuEngine lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, July 15th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $140.00 to $155.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Finally, Citigroup raised their price objective on Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $163.38.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Bear Market

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.